tirzepatide for addiction Weight loss drugs may stop people getting addicted to drugs and alcohol, study finds | Weight-loss drugs Eli Lilly to test its

Biol Trace Elem Res (2011) 141:17083

GLP-1 crosses the blood-brain barrier in limited amounts, but more importantly, it activates vagal afferent neurons that communicate with central appetite centers

The lactation study used injectable semaglutide and found undetectable milk levels

doi: 10.1046/j.1471-4159.1995.65062561.x

Its important to monitor these reactions during treatment

And the two market leaders are not standing still either: Novo has initiated a pipeline expansion program across six trials spanning obesity, sleep apnoea, and knee osteoarthritis, while Lilly is studying Foundayo for type 2 diabetes, sleep apnoea, hypertension, and other indications